Skip to main content

Parkinson's Disease clinical trials at UC Irvine

10 in progress, 4 open to eligible people

Showing trials for
  • A Study of TAK-071 in People With Parkinson Disease

    open to eligible people ages 40-85

    It is hoped that TAK-071 will help people with Parkinson's disease to walk with better balance. The main aim of the study is to check if there is a difference in how participants walk after treatment with TAK-071. Another aim is to see if it improves how participants think and remember. At the first visit, the study doctor will check who can take part. Participants who can take part will be picked for 1 of 2 groups by chance. Both groups will have 2 treatments but in a different order. The treatments are TAK-071 tablets or placebo. In this study, a placebo will look like the TAK-071 but will not have any medicine in it. One group will take TAK-071 for 6 weeks, have at least a 3-week break, then take a placebo for 6 weeks. The other group will take a placebo for 6 weeks, have at least a 3-week break, then take TAK-071 for 6 weeks. The participants will not know the order of their 2 treatments, nor will their study doctors. This is to help make sure the results are more reliable. The participants will visit the clinic at the beginning and end of each treatment for a check-up. 14 days after the 2nd treatment, clinic staff will telephone the participants for a final check-up.

    Irvine, California and other locations

  • Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy

    open to eligible people ages 30-85

    This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the Unified Dyskinesia Rating Scale (UDysRS). Patients who complete the 12-week blinded treatment period may have the option to roll into an open-label safety extension study for an additional 12-month treatment period.

    Irvine, California and other locations

  • Light Therapy for PD - Dose Selection

    open to eligible people ages 45 years and up

    This study aims to determine the most effective dose of light therapy to improve sleep in people with Parkinson's Disease. Four groups of participants will receive bright-white or dim-red light therapy at different times throughout the day.

    Irvine, California and other locations

  • Trial of Parkinson's And Zoledronic Acid

    open to eligible people ages 60 years and up

    This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 3500 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the National Institute of Aging.

    Irvine, California and other locations

  • A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease

    Sorry, in progress, not accepting new patients

    This is a phase 2 study designed to assess the safety, tolerability and efficacy of NLY01 in subjects with early untreated Parkinson's disease (PD). Evidence suggests NLY01, a pegylated form of exenatide, may be beneficial in PD and is being developed as a potential treatment for neurodegenerative disorders.

    Irvine, California and other locations

  • A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

    Sorry, not currently recruiting here

    The purpose of this study is to measure safety and efficacy of buntanetap capsules compared with placebo capsules in participants with early PD. Study details include: - The study duration will be up to 7-8 months. - The double-blind treatment duration will be up to 6 months. - There will be 5 in-clinic visits and 7 phone calls

    Orange, California and other locations

  • GDNF Gene Therapy for Parkinson's Disease

    Sorry, not currently recruiting here

    The objective of this Phase 1b investigation is to evaluate the safety and potential clinical effect of AAV2-GDNF delivered to the putamen in subjects with either a recent or a long-standing diagnosis of PD.

    Irvine, California and other locations

  • Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease

    Sorry, in progress, not accepting new patients

    This clinical trial is designed to test whether surgically injecting nerve cells that make dopamine into the brain of Parkinson's disease patients is safe, and to monitor for potential side effects.

    Orange, California and other locations

  • VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)

    Sorry, in progress, not accepting new patients

    The objectives of this study are to assess the efficacy, safety and tolerability of VY-AADC02 in Patients with Parkinson's Disease with Motor Fluctuations.

    Irvine, California and other locations

  • Noninterventional Study Evaluating Parkinson's Disease Diary Use

    Sorry, not currently recruiting here

    This study aims to evaluate the impact of the frequency of assessments on the variability over time, reliability, and compliance for the Parkinson's disease (PD) diary in patients with PD in whom medications do not provide adequate control of symptoms.

    Orange, California and other locations

Our lead scientists for Parkinson's Disease research studies include .

Last updated: